Connect Biopharma Holdings Limited's Cash & cash equivalent grew by 372.02 % in the Q2 2026 sequentially, faster than Current Liabilities, this led to improvement in Connect Biopharma Holdings Limited's Quick Ratio to 1.93, Quick Ratio remained below Connect Biopharma Holdings Limited average.

Within Major Pharmaceutical Preparations industry 290 other companies have achieved higher Quick Ratio than Connect Biopharma Holdings Limited in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 931 to 1433.

Explain Quick Ratio?
How much Cash & cash equivalents CNTB�s has?
What are CNTB�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

CNTB Quick Ratio	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2
Y / Y Current Liabilities Change	387.82 %	41.03 %	40.7 %	-	-90.71 %
Y / Y Cash & cash equivalent Change	-22.47 %	-86.01 %	-50.98 %	149.66 %	-80.8 %
Quick Ratio MRQ	1.93	1.62	2.82	11.02	12.16
CNTB's Total Ranking	# 1433	# 931	# 0	# 575	# 375
Seq. Current Liabilities Change	295.84 %	-69.75 %	296.21 %	2.82 %	14.44 %
Seq. Cash & cash equivalent Change	372.02 %	-82.6 %	1.32 %	-6.85 %	-14.84 %

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 291
Healthcare Sector	# 506
Overall Market	# 1433

Quick Ratio Statistics
High	Average	Low
26.58	9.12	1.62
(Dec 31 2020)		(Mar 31 2026)

Financial Statements
Connect Biopharma Holdings Limited's Current Liabilities	$ 16 Millions	Visit CNTB's Balance sheet
Connect Biopharma Holdings Limited's Cash & cash equivalent	$ 32 Millions	Visit CNTB's Balance sheet
Source of CNTB's Sales		Visit CNTB's Sales by Geography

Cumulative Connect Biopharma Holdings Limited's Quick Ratio

CNTB's Quick Ratio for the trailling 12 Months

CNTB Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	135.11 %	-49.52 %	-66.65 %	-77.07 %	-85.34 %
Y / Y Cash & cash equivalent TTM Growth	-37.07 %	-64.99 %	-59.97 %	-50.67 %	-64.03 %
Quick Ratio TTM	3.05	5.04	7.06	10.55	11.4
Total Ranking TTM	# 3699	# 2927	# 0	# 2211	# 2776
Seq. Current Liabilities TTM Growth	52.88 %	5.14 %	20.33 %	21.56 %	-67.17 %
Seq. Cash & cash equivalent TTM Growth	-7.39 %	-24.94 %	-19.51 %	12.48 %	-48.48 %

Quick ratio ranking by company, industry and sector >> Back to CNTB Financial Strength Comparisons >> Go to Compare CNTB Quick Ratio to its Competitors

News about Connect Biopharma Holdings Limited Quick Ratio

Connect Biopharma Reports Positive Phase 2 Trial Results for Rademikibart in Uncontrolled Asthma Patients

In a significant advancement in the management of moderate-to-severe uncontrolled asthma, Connect Biopharma has announced the publication of promising data from a global Phase 2 trial of Rademikibart, their investigational therapeutic agent. The findings indicate a rapid onset of action, with significant improvements in lung function observed within one week of treatment, effects that were sustained throughout the 24-week study period.Asthma, a chronic inflammatory disease of the airways, affects millions of people globally, with a substantial subset of patients experiencing inadequately controlled symptoms despite standard therapies. The results from Connect Biopharma s trial suggest that Rademikibart may offer a new avenue for these patients, providing a tangible improvement in lung function early in the treatment process. The trial participants demonstrated a marked improvement in their pulmonary function metrics, indicating that Rademikibart effectively targets the underlying pathophysiology of asthma. The rapid therapeutic effect is particularly noteworthy, as it addresses a critical need for faster relief in patients facing severe symptoms.

On the trailing twelve months basis Due to in Current Liabilities in the Q2 2026 to $16.30 millions, cumulative Quick Ratio decreased to 3.05 below the average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 427 other companies have achieved higher Quick Ratio than Connect Biopharma Holdings Limited. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 2927 to 3699.

Explain Quick Ratio?
How much Cash & cash equivalents CNTB�s has?
What are CNTB�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 428
Healthcare Sector	# 871
Within the Market	# 3699

trailing twelve months Quick Ratio Statistics
High	Average	Low
16.04	8.4	3.36
(Sep 30 2025)		(Jun 30 2026)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Neurogene Inc	5.23	$ 112.485 Millions	$ 21.505 Millions
Lexaria Bioscience Corp	5.20	$ 3.642 Millions	$ 0.701 Millions
Barinthus Biotherapeutics Plc	5.19	$ 59.295 Millions	$ 11.423 Millions
Immuneering Corporation	5.14	$ 41.731 Millions	$ 8.116 Millions
Lyell Immunopharma Inc	5.12	$ 204.102 Millions	$ 39.867 Millions
Altimmune inc	5.04	$ 63.008 Millions	$ 12.501 Millions
Rani Therapeutics Holdings Inc	5.02	$ 53.391 Millions	$ 10.638 Millions
Phio Pharmaceuticals Corp	4.99	$ 12.996 Millions	$ 2.606 Millions
Immunic Inc	4.96	$ 155.098 Millions	$ 31.260 Millions
Silo Pharma Inc	4.90	$ 5.227 Millions	$ 1.066 Millions
Atossa Therapeutics Inc	4.81	$ 26.204 Millions	$ 5.451 Millions
Calcimedica Inc	4.71	$ 18.600 Millions	$ 3.950 Millions
Kala Bio inc	4.70	$ 7.229 Millions	$ 1.538 Millions
Septerna Inc	4.69	$ 372.322 Millions	$ 79.316 Millions
Viking Therapeutics Inc	4.57	$ 501.663 Millions	$ 109.656 Millions
Camp4 Therapeutics Corporation	4.51	$ 86.398 Millions	$ 19.142 Millions
Rein Therapeutics Inc	4.49	$ 43.627 Millions	$ 9.709 Millions
Quantum Cyber N v	4.46	$ 13.415 Millions	$ 3.005 Millions
Maia Biotechnology Inc	4.41	$ 27.596 Millions	$ 6.258 Millions
Azitra Inc	4.40	$ 6.728 Millions	$ 1.531 Millions
Cypherpunk Technologies Inc	4.39	$ 7.624 Millions	$ 1.737 Millions
Rigel Pharmaceuticals Inc	4.35	$ 225.347 Millions	$ 51.858 Millions
Biohaven Ltd	4.28	$ 267.866 Millions	$ 62.658 Millions
Longeveron Inc	4.20	$ 18.104 Millions	$ 4.307 Millions
Vistagen Therapeutics Inc	4.15	$ 46.439 Millions	$ 11.192 Millions
Gyre Therapeutics Inc	4.12	$ 86.289 Millions	$ 20.957 Millions
Seaport Therapeutics Inc	4.11	$ 64.423 Millions	$ 15.674 Millions
Prelude Therapeutics Inc	3.99	$ 151.757 Millions	$ 38.042 Millions
Alx Oncology Holdings Inc	3.97	$ 22.753 Millions	$ 5.731 Millions
Actinium Pharmaceuticals Inc	3.94	$ 36.473 Millions	$ 9.260 Millions

Date modified: 2026-09-03T11:39:10+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.